Terms: = Gastric cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
237 results:
1. State-of-the-Art Advancements in Gastroesophageal cancer Treatment: Harnessing Biomarkers for Precision Care.
Balmaceda NB; Petrillo A; Krishnan M; Zhao JJ; Kim S; Klute KA; Sundar R
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431060. PubMed ID: 38771996
[TBL] [Abstract] [Full Text] [Related]
2. A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced fgfr2/3-driven Solid Tumors.
Garmezy B; Borad MJ; Bahleda R; Perez CA; Chen LT; Kato S; Oh DY; Severson P; Tam BY; Quah CS; Harding JJ
Cancer Res Commun; 2024 Apr; 4(4):1165-1173. PubMed ID: 38602417
[TBL] [Abstract] [Full Text] [Related]
3. Genomic and Pathologic Profiling of Very Well-Differentiated gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
[TBL] [Abstract] [Full Text] [Related]
4. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract] [Full Text] [Related]
5. Investigating fgfr2 gene as a blood-based epigenetic biomarker in gastric cancer.
Aleyasin SA; Moradi A; Abolhasani N; Abdollahi M
Mol Biol Rep; 2024 Feb; 51(1):253. PubMed ID: 38302798
[TBL] [Abstract] [Full Text] [Related]
6. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach.
Wei J; Ji K; Zhang Y; Zhang J; Wu X; Ji X; Zhou K; Yang X; Lu H; Wang A; Bu Z
Cell Oncol (Dordr); 2024 Apr; 47(2):677-693. PubMed ID: 37943484
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Potential Genomic Alterations Using Pan-cancer Cell-Free DNA Next-Generation Sequencing in Patients With gastric cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract] [Full Text] [Related]
8. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
9. MDM2 amplification is rare in gastric cancer.
Abdullazade S; Behrens HM; Krüger S; Haag J; Röcken C
Virchows Arch; 2023 Dec; 483(6):795-807. PubMed ID: 37821635
[TBL] [Abstract] [Full Text] [Related]
10. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract] [Full Text] [Related]
11. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract] [Full Text] [Related]
12. Oncogenic structural aberration landscape in gastric cancer genomes.
Saito-Adachi M; Hama N; Totoki Y; Nakamura H; Arai Y; Hosoda F; Rokutan H; Yachida S; Kato M; Fukagawa A; Shibata T
Nat Commun; 2023 Jun; 14(1):3688. PubMed ID: 37349325
[TBL] [Abstract] [Full Text] [Related]
13. [Study of fgfr2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization].
Raskin GA; Mukhina MS; Kravtsova ED; Tsimafeyeu IV; Tyulandin SA; Belyak NP; Kleshchev MA; Orlova RV
Arkh Patol; 2023; 85(3):40-45. PubMed ID: 37272439
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of a Selective and Orally Bioavailable fgfr2 Degrader for Treating gastric cancer.
Ma L; Li Y; Luo R; Wang Y; Cao J; Fu W; Qian B; Zheng L; Tang L; Lv X; Zheng L; Liang G; Chen L
J Med Chem; 2023 Jun; 66(11):7438-7453. PubMed ID: 37220310
[TBL] [Abstract] [Full Text] [Related]
15. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
16. Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation.
Zhang M; Yasen M; Lu S; Ma DN; Chai Z
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985681
[TBL] [Abstract] [Full Text] [Related]
17. A phase 1b study of the allosteric extracellular fgfr2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Tsimafeyeu I; Statsenko G; Vladimirova L; Besova N; Artamonova E; Raskin G; Rykov I; Mochalova A; Utyashev I; Gorbacheva S; Kazey V; Gavrilova E; Dragun N; Moiseyenko V; Tjulandin S
Invest New Drugs; 2023 Apr; 41(2):324-332. PubMed ID: 36907947
[TBL] [Abstract] [Full Text] [Related]
18. Comparative Meta-analysis of Adipose Tissue Transcriptomics Data in PCOS Patients and Healthy Control Women.
Saedi S; Panahi R; Orak N; Jafarzadeh Shirazi MR
Reprod Sci; 2023 Jun; 30(6):1823-1833. PubMed ID: 36512189
[TBL] [Abstract] [Full Text] [Related]
19. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract] [Full Text] [Related]
20. fgfr2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
[TBL] [Abstract] [Full Text] [Related]
[Next]
